studies on tirzepatide Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice Understand GLP-1/GIP Dual Agonist Tirzepatide

In some cases, things are more severe

Childress adds

For example, Muayad et al compared 61,998 patients with diabetes using GLP-1 RAs with metformin users in the US Collaborative Network of the TriNetX EHR database to calculate the risk of developing ocular hypertension or primary open-angle glaucoma, requiring topical glaucoma medication, or requiring laser trabeculoplasty

Tirzepatide (Mounjaro, Zepbound) works through a dual mechanism as both a GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist

This limitation explains why many patients experience symptom recurrence immediately upon discontinuing their medications

2018;20(Suppl 1):521